News | Embolization devices | December 17, 2015

ArtVentive Medical Testing Next-Generation EOS Vessel Occlusion Technology

Upgraded device features reduced profile, reversibility for immediate and permanent vessel occlusion in arterial and venous settings

December 17, 2015 — ArtVentive Medical Group conducted its first animal study of its next generation of the ArtVentive Endoluminal Occlusion System (EOS Gen II). The EOS is designed for use in the peripheral vasculature and offers immediate and permanent vessel occlusion in arterial and venous settings.

According to ArtVentive President and CTO Leon Rudakov, Ph.D., the second-generation EOS device offers several advantages, including profile reductions, reversibility, enhanced control over deployment and the opportunity to advance into new indications.

The ArtVentive EOS is a catheter-based, self-expandable device, which facilitates permanent and immediate occlusion of peripheral vessels. The device is designed to serve as a safe and reliable alternative to major surgery in certain cases.

For more information: www.artventivemedical.com


Related Content

Feature | Cath Lab | Kyle Hardner

Since receiving FDA approval in 2016, intravascular lithotripsy (IVL) systems have grown in popularity among ...

Home November 14, 2025
Home
News | Cath Lab

Nov. 11, 2025 — FastWave Medical has successfully completed enrollment in its 30-patient coronary feasibility study and ...

Home November 13, 2025
Home
News | Cath Lab

Oct. 28, 2025 — Results from the first-of-its-kind randomized PROCTOR trial found that a strategy of saphenous vein ...

Home November 04, 2025
Home
News | Cath Lab

Oct. 27, 2025 — Results from the PREVUE-VALVE study suggest that there are currently at least 4.7 million people aged 65 ...

Home October 29, 2025
Home
News | Cath Lab

Oct. 25, 2025 — Medtronic plc has announced the launch of the Stedi Extra Support guidewire, designed to enhance ...

Home October 28, 2025
Home
News | Cath Lab

Oct. 27, 2025 — Elixir Medical, a developer of technologies to treat cardiovascular disease, has announced new clinical ...

Home October 28, 2025
Home
News | Cath Lab

Oct. 22, 2025 — Heartflow, Inc. has introduced Heartflow PCI Navigator, the newest addition to the Heartflow One ...

Home October 23, 2025
Home
News | Cath Lab

Oct. 15, 2025 — Stereotaxis recently announced it has obtained CE Mark in Europe and submitted a 510(k) application to ...

Home October 16, 2025
Home
News | Cath Lab

Oct. 7, 2025 — Medtronic has announced the full distribution of the Neuroguard IEP System (Neuroguard) after a ...

Home October 07, 2025
Home
News | Cath Lab

Sept. 22, 2025 — Nicklaus Children's Heart Institute in Miami, Florida, is now offering bedside transcatheter patent ...

Home September 23, 2025
Home
Subscribe Now